Alimera Announces Positive 36-Month Results From The Completed Phase 3 FAMET Study Of ILUVIEN® In Patients With Diabetic Macular Edema

28.4% and 29.0% demonstrated improvement in best corrected visual acuity (BCVA) of 15 letters from baseline, at three years. Statistical significance seen in both trials as late as month 33.